List of Excipients in Branded Drug CHENODAL

Generic Drugs Containing CHENODAL

Company	Ingredient	NDC	Excipient
Travere Therapeutics	chenodiol	68974-876	CELLULOSE, MICROCRYSTALLINE
Travere Therapeutics	chenodiol	68974-876	GLYCERIN
Travere Therapeutics	chenodiol	68974-876	MAGNESIUM STEARATE

What are the Most Frequently-Used Excipients in CHENODAL?

# Of NDCs	Excipient
1	CELLULOSE, MICROCRYSTALLINE
1	GLYCERIN
1	MAGNESIUM STEARATE

CHENODAL Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

CHENODAL is an oral chenodiol, or chenodeoxycholic acid, product used in the treatment of cerebrotendinous xanthomatosis (CTX). Its strongest commercial opportunities are pediatric liquid delivery, capsule or sprinkle formulations, adherence-focused dose packaging, and geographic expansion. The active ingredient has limited composition-of-matter protection, so commercial differentiation depends on formulation performance, regulatory exclusivity, manufacturing control, and supply reliability rather than on a new-molecule patent.

What is CHENODAL and what active ingredient does it contain?

CHENODAL contains chenodiol, also known as chenodeoxycholic acid. It is a naturally occurring bile acid that reduces abnormal bile-acid synthesis and is used as replacement therapy in CTX.

Attribute	CHENODAL profile
Active ingredient	Chenodiol
Chemical name	Chenodeoxycholic acid
Dosage form	Oral tablet
Strength	250 mg
Therapeutic area	Cerebrotendinous xanthomatosis
FDA pathway	Prescription drug approval under an existing chenodiol regulatory framework
Primary patient population	Patients with a rare inherited bile-acid synthesis disorder
Key formulation issue	Poor aqueous solubility and dose administration in pediatric or neurologically impaired patients
Main commercial barrier	Small patient population and high dependence on reliable specialty distribution

The product's commercial value is driven by the rarity and seriousness of CTX, not by broad primary-care demand. CTX treatment is generally chronic and may begin in childhood, creating a sustained need for convenient administration and stable supply.

What is the FDA regulatory status of CHENODAL?

CHENODAL has been associated with FDA approval for chenodiol use in CTX. The product history is complicated by earlier chenodiol approvals and marketing changes for gallstone treatment. FDA records should be reviewed by NDA number and supplement history because the status of the original chenodiol product, later commercial labels, and successor products is not identical.

The key regulatory points are:

1. Chenodiol is an established active pharmaceutical ingredient with historical human use.
2. CTX is an orphan disease with a small U.S. population.
3. The regulatory value of a new formulation would likely arise from improved administration, stability, pediatric usability, or a new dosage form.
4. A reformulated chenodiol product would likely require a 505(b)(2) application if it relies on FDA findings for an existing chenodiol product while introducing a material formulation or dosage-form change.
5. A generic tablet could pursue an ANDA if it can demonstrate pharmaceutical equivalence and bioequivalence to the applicable reference product.

The FDA approved Ctexli, another chenodiol product, for CTX in 2025. Ctexli is commercially relevant because it confirms continuing regulatory and market interest in chenodiol for CTX, while creating a direct product comparison for CHENODAL. The two products should not be treated as interchangeable without reviewing their labels, dosage strengths, inactive ingredients, and FDA-approved substitutability status.[1]

What excipients are suitable for a chenodiol tablet?

Chenodiol presents a conventional formulation challenge: it is a lipophilic bile acid with low water solubility. Excipient selection should focus on wetting, dispersion, powder flow, tablet robustness, dissolution, and chemical stability.

Candidate excipient classes

Formulation function	Candidate excipients	Commercial rationale
Diluent	Microcrystalline cellulose, lactose monohydrate, mannitol, dibasic calcium phosphate	Supports tablet mass and compression
Binder	Povidone, copovidone, hydroxypropyl cellulose	Improves granule and tablet strength
Disintegrant	Crospovidone, croscarmellose sodium, sodium starch glycolate	Supports rapid tablet breakup
Wetting agent	Sodium lauryl sulfate, poloxamer, polysorbate	Can improve contact between drug particles and dissolution medium
Lubricant	Magnesium stearate, sodium stearyl fumarate	Supports manufacturing and ejection
Glidant	Colloidal silicon dioxide	Improves powder flow and content uniformity
Solubilization aid	Cyclodextrin derivatives, surfactant systems, lipid excipients	May improve dissolution but can increase regulatory and stability complexity
Taste masking	Polymer coating, ion-exchange resin, lipid matrix, flavor system	Relevant to pediatric liquid and dispersible products
Moisture control	Desiccant packaging, low-moisture excipient system, high-barrier blister	Helps preserve chemical and physical stability

The preferred first-line development strategy is a robust immediate-release tablet using a conventional diluent-binder-disintegrant system, with dissolution enhancement addressed through particle engineering, wetting agents, or controlled granulation. A high-complexity lipid or cyclodextrin system may improve exposure but could introduce additional safety, manufacturing, and regulatory issues.

What excipient strategy could improve CHENODAL?

A commercially attractive CHENODAL reformulation should solve a defined administration problem rather than merely replace one inactive ingredient with another.

1. Pediatric oral liquid

A ready-to-use suspension or powder-for-reconstitution product is the most important formulation opportunity. CTX can present in childhood, and long-term tablet administration may be difficult for younger patients or patients with neurologic impairment.

The formulation should address:

• Uniform dose delivery after shaking
• Acceptable sedimentation and redispersion
• Low microbial risk
• Chemical stability over the intended in-use period
• Low viscosity for oral syringes
• Taste masking without excessive surfactant use
• Compatibility with enteral feeding tubes
• Packaging that supports small, weight-based doses

A suspension may be preferable to a clear solution because chenodiol's low solubility could limit drug loading and increase excipient burden in a fully solubilized liquid.

2. Dispersible or orally disintegrating tablet

A dispersible tablet could preserve the cost and stability advantages of a solid dosage form while reducing swallowing difficulty. The product could be administered in a small volume of water or soft food.

Critical development variables include:

• Rapid dispersion without clumping
• Dose recovery from the administration vessel
• Acceptable mouthfeel
• Low friability
• Stability under humid conditions
• Absence of a bitter or bile-acid taste

An orally disintegrating tablet may provide a stronger lifecycle-management position than a conventional tablet, but taste masking and dose uniformity would be more difficult.

3. Sprinkle capsule

A hard capsule containing coated multiparticulates or granules could allow administration with soft food. This approach is relevant for children who cannot swallow tablets but can consume applesauce or similar vehicles.

A multiparticulate product creates potential claims around:

• Coated chenodiol particles
• Uniform dosing after capsule opening
• Reduced taste perception
• Food compatibility
• Improved dissolution
• Administration through feeding tubes

The principal risk is dose segregation. Chenodiol particles must remain uniformly distributed during capsule filling, opening, and transfer into food.

4. Improved tablet dissolution

A direct formulation program could use micronized chenodiol, wetting agents, or a solid-dispersion approach. The commercial objective would be more consistent dissolution rather than necessarily higher systemic exposure.

Potential intellectual-property claims could cover:

• Specific particle-size distributions
• Excipient ratios
• Granulation conditions
• Dissolution profiles
• Stability specifications
• Manufacturing processes

Particle-size claims are more defensible when tied to measurable dissolution and bioavailability results. A broad claim to micronized chenodiol alone would face greater validity and obviousness risk.

What patents protect CHENODAL and chenodiol?

The original chenodiol composition of matter is old and does not provide meaningful remaining U.S. exclusivity. The likely protection categories are formulation, dosage form, method of treatment, manufacturing process, and regulatory exclusivity.

Protection category	Expected status or commercial relevance
Original chenodiol molecule	Historical protection expired
Original gallstone-use patents	Historical protection expired or commercially weak
CTX method-of-use claims	Potentially relevant where claim scope and term remain available
Orphan-drug exclusivity	Historically important for the CTX indication; term depends on the original approval date and applicable FDA records
Tablet formulation	Potentially protectable if supported by a novel formulation and performance data
Pediatric liquid	Strongest practical lifecycle-management opportunity
Manufacturing process	Useful for supply control and process differentiation
Trade secrets	Important for particle engineering, granulation, coating, and stability control

No business plan should assume that the CHENODAL brand has a durable patent barrier comparable to a recently launched small molecule. The commercial defense is more likely to come from regulatory exclusivity, physician familiarity, specialty distribution, manufacturing know-how, and switching friction.

Patent diligence should review the USPTO Patent Center, FDA Orange Book listings, FDA approval letters, and the patent disclosures for both CHENODAL and competing chenodiol products. A patent number should not be treated as commercially material unless it is listed for the relevant product, has enforceable claims, and has a term extending beyond the planned launch date.

When does CHENODAL lose exclusivity?

CHENODAL's exclusivity must be separated into three categories:

1. Patent exclusivity.
2. Orphan-drug exclusivity.
3. Regulatory exclusivity associated with the applicable NDA.

The original active ingredient does not provide a current molecule-level barrier. The most relevant historic protection was likely the orphan exclusivity associated with the CTX indication. Orphan exclusivity is indication-specific and does not automatically block all chenodiol products for all uses.

A competitor could still face:

• Difficulty establishing an adequate reference product for an ANDA.
• Limited commercial volume because CTX is rare.
• Need for specialty distribution and reimbursement support.
• Clinical and regulatory complexity for a new pediatric dosage form.
• Risk that a formulation patent, if valid and listed, delays launch.

The launch timing for a generic tablet would depend on FDA reference-product designation, patent certifications, any Paragraph IV notice, litigation, and the commercial decision to serve a small patient population.

What Paragraph IV challenges could affect CHENODAL?

A Paragraph IV challenge would be relevant only if a listed patent covers the reference product and the ANDA applicant certifies that the patent is invalid, unenforceable, or not infringed.

For CHENODAL, the most plausible targets would be:

• Tablet composition claims
• Specific dissolution or release characteristics
• CTX method-of-use claims
• Pediatric administration claims
• Manufacturing-process claims, if listed and applicable

A Paragraph IV case would have limited value if the product has no active Orange Book-listed patents. In that situation, an ANDA applicant could avoid patent litigation while still facing the economic challenge of serving a small rare-disease market.

The commercial risk is therefore asymmetric. A generic can create price pressure without needing to defeat a large portfolio of composition patents, but the small patient population may delay entry because development and launch costs are difficult to recover.

What commercial opportunities exist for CHENODAL excipient innovation?

U.S. lifecycle management

The most attractive U.S. opportunity is a pediatric liquid or dispersible product with a clearly differentiated label. A new dosage form could support a 505(b)(2) strategy and potentially obtain its own regulatory exclusivity or patent protection if the formulation is novel.

International expansion

Many markets lack a reliable supply of chenodiol for CTX. Commercial opportunities exist in Europe, the United Kingdom, Canada, Australia, Japan, and selected Middle Eastern markets, subject to local orphan-drug and pricing rules.

A stable powder-for-reconstitution could reduce shipping and storage costs compared with a ready-to-use suspension. A tablet may remain preferable in markets where cold-chain-free distribution and long shelf life are important.

Specialty pharmacy and adherence services

Packaging can become part of the commercial product:

• Weight-based dosing calendars
• Bottles with oral syringes
• Unit-dose blister packs
• Refill synchronization
• Caregiver instructions
• Temperature and moisture-resistant packaging

These measures have limited patent value but can improve persistence and reduce dispensing errors.

Licensing and partnership targets

Potential partners include:

• Specialty pharmaceutical companies with rare-disease portfolios
• Contract development and manufacturing organizations with lipid or suspension expertise
• Regional distributors with orphan-drug access
• Diagnostic companies involved in CTX testing
• Academic centers with CTX patient registries

A licensing transaction would be more attractive for a differentiated dosage form with global rights than for an unprotected conventional chenodiol tablet.

How strong is the CHENODAL patent estate?

The estate is likely weak at the molecule level and potentially moderate at the formulation level.

Estate component	Relative strength
Chenodiol composition of matter	Low
Historical gallstone use	Low
CTX method of use	Moderate, but term and scope are decisive
Conventional 250 mg tablet	Low to moderate
Pediatric liquid	Moderate to strong if supported by novel stability and dosing data
Multiparticulate sprinkle product	Moderate
Manufacturing process	Moderate as trade secret; variable as patent
Orphan regulatory protection	Potentially significant but time-limited

The strongest investment thesis is not a broad patent moat. It is a focused lifecycle strategy that combines differentiated administration, reliable supply, regulatory exclusivity, and specialty-market execution.

What generic launch scenarios exist for CHENODAL?

Scenario	Likely effect
No viable generic reference pathway	CHENODAL retains pricing power, but market remains supply-constrained
Conventional tablet ANDA	Moderate price erosion; limited uptake due to rare disease
Pediatric liquid launch	Higher clinical utility and potential premium pricing
Ctexli or another branded chenodiol competitor	Increased payer and physician comparison
Authorized generic	Faster price competition with lower substitution barriers
Compounded suspension	Local access solution, but variable quality and limited scalability
International low-cost entrant	Potential regional price pressure

A generic tablet is unlikely to eliminate the value of a well-designed pediatric dosage form. The strongest defense is segmentation: maintain the tablet for stable adult patients while using the liquid, dispersible, or sprinkle product for newly diagnosed children and patients with administration difficulties.

What regulatory and manufacturing barriers matter most?

The major barriers are formulation reproducibility and clinical usability rather than active-ingredient synthesis.

Key manufacturing risks include:

• Variable particle size
• Poor powder flow
• Content-uniformity failures at low dose
• Inadequate wetting and dissolution
• Tablet sticking or capping
• Suspension sedimentation
• Taste-mask failure
• Excipient incompatibility
• Moisture-driven degradation or physical change
• Inconsistent dose recovery through feeding tubes

Manufacturers should qualify more than one source for critical excipients, particularly surfactants, polymers, and specialty coating materials. A dual-source strategy reduces supply interruption risk in a rare-disease market where backorders can rapidly affect treatment continuity.

Key Takeaways

• CHENODAL contains chenodiol, an established bile acid used in CTX.
• The original molecule does not provide a meaningful current composition-of-matter barrier.
• The strongest lifecycle opportunity is a pediatric oral suspension or powder-for-reconstitution.
• Dispersible tablets and sprinkle capsules are credible second-generation dosage forms.
• Excipient selection should prioritize wetting, dissolution, taste masking, dose uniformity, and stability.
• A 505(b)(2) pathway may be appropriate for a differentiated chenodiol dosage form.
• Orphan-drug exclusivity and method-of-use protection are time-limited and indication-specific.
• Generic tablet entry could create price pressure, but the small CTX population limits the commercial incentive.
• A differentiated pediatric product can preserve value even after conventional tablet competition.
• Ctexli creates a direct branded comparator and confirms continuing commercial interest in chenodiol.

FAQs

Can CHENODAL be reformulated as a liquid suspension?

Yes. A suspension is technically plausible and may be more practical than a fully solubilized liquid because chenodiol has limited aqueous solubility. The formulation would require validated redispersion, dose uniformity, microbial control, taste masking, and in-use stability.

Which excipient is most important for improving chenodiol dissolution?

No single excipient is universally optimal. A combination of particle-size control, wetting agent, disintegrant, and granulation process is more likely to improve dissolution than a single additive. Surfactants and cyclodextrins require careful safety and stability evaluation.

Is CHENODAL interchangeable with Ctexli?

Interchangeability cannot be assumed. The products should be compared by FDA label, dosage form, strength, inactive ingredients, approved indication, and pharmacy-substitution status.

Could a new CHENODAL formulation receive orphan-drug exclusivity?

A new formulation does not automatically receive separate orphan exclusivity merely because it treats the same rare disease. Eligibility depends on the product, indication, sponsor, clinical distinction, and FDA orphan-drug rules.

What is the best patent strategy for a chenodiol pediatric product?

The strongest strategy would combine composition claims directed to a specific excipient system, process claims covering manufacture, performance claims tied to dissolution or dose recovery, and method claims covering pediatric administration where legally supportable.

References

1. U.S. Food and Drug Administration. (2025). Ctexli (chenodiol) prescribing information. FDA.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA.
3. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database. FDA.
4. U.S. Food and Drug Administration. (n.d.). Orphan drug designation and approval database. FDA.
5. U.S. Food and Drug Administration. (n.d.). Approved drug product labels and regulatory submissions for chenodiol products. FDA.
6. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP.